Accession Therapeutics
Accession Therapeutics develops targeted immuno-oncology treatments for solid cancers using its proprietary Trocept stealth virus platform. The technology is designed to engineer viral entry into cancer cells while bypassing healthy tissue to deliver therapeutic payloads. Its lead candidate, TROCEPT-01 (ATTR-01), is currently in Phase 1 clinical trials for the treatment of intractable and widespread forms of cancer.
Visit websiteOxford, UK
Healthtech
Biotechnology
Oncology
Pharmaceuticals
Funding summary
- Total raised
- €19.2M
- Funding rounds
- 1
Investors in Accession Therapeutics
Investors on record for Accession Therapeutics. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Accession Therapeutics?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors